225Ac ‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models

ConclusionsThere results suggest that the combination of225Ac ‐lintuzumab with venetoclax is a promising therapeutic strategy for the treatment of patients with venetoclax‐resistant AML.Clinical trial of this combination therapy (NCT03867682) is currently ongoing.

Source: Cancer Medicine - December 21, 2020 Category: Cancer & Oncology Authors: Ravendra Garg, Kevin J. H. Allen, Wojciech Dawicki, Eileen M. Geoghegan, Dale L. Ludwig, Ekaterina Dadachova Tags: ORIGINAL RESEARCH Source Type: research